Inrig Jula
Transaction: 06/22/2026
SELL
Change
-468
Price
Not reported
Filing
06/22/2026
Type
SELL
Travere Therapeutics, Inc.
TVTX • Biotechnology
$52.50
— 0.00 (0.00%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$4.67B
Growth
—
Cash Flow
1/5
Trend
Volatile
Evidence
Positive revenue growth · 25.7%Positive free cash flow · 0.42Healthy liquidity · 2.74High debt level · 2.86Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 6, 2026, 12:42 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$52.50
Change0.00%
Shares Out93.48M
Market Cap$4.67B
Enterprise Value$4.79B
52W Range15.60 - 66.24
Beta1.11
P/E-107.54
P/S7.90
P/B190.60
P/FCF-689.48
EV/Sales8.11
Price$52.50
Change0.00%
Shares Out93.48M
Market Cap$4.67B
Enterprise Value$4.79B
52W Range15.60 - 66.24
Beta1.11
P/E-107.54
P/S7.90
P/B190.60
P/FCF-689.48
EV/Sales8.11
EV/EBITDA3,104.75
EV/FCF-707.15
Earnings Yield-0.93%
FCF Yield-0.15%
Dividend Yield0.00%
Gross Margin97.89%
Oper. Margin-12.80%
Profit Margin-5.21%
Debt/Eq2.86
Current Ratio2.74
Quick Ratio2.70
Target$76.00
Target Upside44.76%
Target Median$74.00
Target Range67.00 - 89.00
Volume6.31M
Avg Volume2.08M
EPS Surprise-0.09
Investment DNA
How strong this company looks for long-term investors
45
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
58/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
26/100
Why this score▼
Positive revenue growth · 25.7%Positive free cash flow · 0.42Healthy liquidity · 2.74High debt level · 2.86Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 18 analyst votes · 2026-10-20
92/100
Bullish
Bullish
15
Hold
3
Bearish
0
Price Target
2026-08-07
Low
$49.00
Mean
$62.75
Median
$66.00
High
$70.00
Insider Transactions
Recent executive and insider activity
Baynes Roy D.
Transaction: 06/12/2026
SELL
Change
-4,500
Price
$21.38
Filing
06/16/2026
Type
SELL
Baynes Roy D.
Transaction: 06/12/2026
SELL
Change
-4,500
Price
$50.00
Filing
06/16/2026
Type
SELL
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Inrig Jula | SELL | -468 | Not reported | 06/22/2026 | 06/22/2026 |
| Baynes Roy D. | SELL | -4,500 | $21.38 | 06/12/2026 | 06/16/2026 |
| Baynes Roy D. | SELL | -4,500 | $50.00 | 06/12/2026 | 06/16/2026 |
| Coughlin Timothy | SELL | -10,000 | $26.52 | 06/12/2026 | 06/16/2026 |
| Coughlin Timothy | SELL | -10,000 | $50.07 | 06/12/2026 | 06/16/2026 |
| Baynes Roy D. | BUY | +12,000 | $42.26 | 05/19/2026 | 05/21/2026 |
| Baynes Roy D. | BUY | +4,000 | Not reported | 05/19/2026 | 05/21/2026 |
| Bruhn Suzanne Louise | BUY | +12,000 | $42.26 | 05/19/2026 | 05/21/2026 |
| Bruhn Suzanne Louise | BUY | +4,000 | Not reported | 05/19/2026 | 05/21/2026 |
| Coughlin Timothy | BUY | +12,000 | $42.26 | 05/19/2026 | 05/21/2026 |
| Coughlin Timothy | BUY | +4,000 | Not reported | 05/19/2026 | 05/21/2026 |
| LYONS GARY A | BUY | +12,000 | $42.26 | 05/19/2026 | 05/21/2026 |
| LYONS GARY A | BUY | +4,000 | Not reported | 05/19/2026 | 05/21/2026 |
| Meckler Jeffrey A | BUY | +12,000 | $42.26 | 05/19/2026 | 05/21/2026 |
| Meckler Jeffrey A | BUY | +4,000 | Not reported | 05/19/2026 | 05/21/2026 |
| Orwin John A | BUY | +12,000 | $42.26 | 05/19/2026 | 05/21/2026 |
| Orwin John A | BUY | +4,000 | Not reported | 05/19/2026 | 05/21/2026 |
| Poole Sandra | BUY | +12,000 | $42.26 | 05/19/2026 | 05/21/2026 |
| Poole Sandra | BUY | +4,000 | Not reported | 05/19/2026 | 05/21/2026 |
| Squarer Ron | BUY | +12,000 | $42.26 | 05/19/2026 | 05/21/2026 |